ERBB2 and breast carcinoma: The NSABP B47 randomized over 3000 women with early stage breast cancer whose HER2 status was negative (1+, and 2+ by IHC of FISH< 2.0) to receive conventional adjuvant chemotherapy with or without 12 months of trastuzumab.